Device Trial Radar · NCT02671968
Real-Time Continuous Glucose Monitoring (RT-CGM) in Patients With Type 1 Diabetes at High Risk for Low Glucose Values Using Multiple Daily Injections (MDI) in Germany (HYPODE-STUDY)
Last checked: Nov 19, 2026Latest source record: Mar 12, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
141
Actual
Start
Feb 2016
Primary completion
Jul 14, 2017
Study completion Oct 24, 2017
Sponsor
- Lead sponsor
- Science Consulting in DiabetesNot on our public-company list
- Sponsor type
- Industry
- Collaborators
- DexCom, Inc. a Delaware corporation, USA; Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm
- First posted
- Feb 2, 2016
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Demonstrate that usage of RT-CGM (Real time continuous glucose monitoring) reduces the frequency of low CGM-recorded glucose events in patients using MDI (Multiple daily injections) that are at risk for hypoglycemic events.
Conditions
- Diabetes
Interventions
Continuous Glucose Monitoring SystemDevice
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in the total number of low glucose events (<55 mg/dl), between baseline and outcome phase (week 22-26) in CGM group and control group (change = subtracting number of follow up events from number of baseline eventsTime frame: For each subject, the experimental phase has an expected duration of up to 7 months
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
Gemeinschaftspraxis Dres. Klausmann
Aschaffenburg, Germany
m&i-Fachklinik Bad Heilbrunn
Bad Heilbrunn, Germany
Forschungsinstitut Diabetes-Akademie Bad Mergentheim (FIDAM)
Bad Mergentheim, Germany
9 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.